Scientists make Parkinson's breakthrough with new weekly injectable drug
The new treatment, which helps with muscle tremors, could potentially replace the need for multiple daily tablets, making life simpler and easier for those living with the condition.
Scientists from the University of South Australia (UniSA) developed a long-acting injectable formulation that delivers a steady dose of levodopa and carbidopa - two key medications for Parkinson's - to last an entire week.
The medication comes in the form of a biodegradable gel that can be injected under the skin or into muscle tissue, where it gradually releases the drugs over a week-long period.
Parkinson's disease is the second most common neurological disorder, affecting more than 8.5 million people worldwide. There are approximately 13,000 people living with Parkinson's disease in Scotland, according to Parkinson's UK.
Currently there is no cure, and the many symptoms of the condition, including tremors, rigidity and slow movement, are currently managed with pills that must be taken several times a day.
But scientists believe the newly developed injection for Parkinson's could revolutionise how the disease is treated, and change the lives of those living with the condition.
Lead researcher Professor Sanjay Garg, from UniSA's Centre for Pharmaceutical Innovation, said: "Our goal was to create a formulation that simplifies treatment, improves patient compliance, and maintains consistent therapeutic levels of medication.
"This weekly injection could be a game-changer for Parkinson's care. Levodopa is the gold-standard therapy for Parkinson's, but its short life span means it must be taken several times a day."
But the new drug can stop the constant hassle of taking multiple pills every day.
The jab can maintain consistent plasma levels in the body by slowly releasing both levodopa and carbidopa steadily throughout the week, which also reduces the risks associated with fluctuating drug concentrations.
UniSA PhD student Deepa Nakmode said: "After years of focused research, it's incredibly rewarding to see our innovation in long-acting injectables for Parkinson's disease reach this stage. Our invention has now been filed for an Australian patent."
The injectable gel combines an FDA-approved biodegradable polymer named PLGA with Eudragit L-100, which is a pH-sensitive polymer. This ensures a controlled and sustained drug release into the body.
Prof Garg concluded: "The implications of this research are profound. By reducing the frequency of dosing from multiple times a day to a weekly injection is a major step forward in Parkinson's therapy.
"We're not just improving how the drug is delivered; we're improving patients' lives."
The scientist says this new technology could also be adapted for other chronic conditions such as cancer, diabetes, neurodegenerative disorders, pain management, and chronic infections.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
US FDA approves Jazz Pharma's drug for rare brain tumor
Aug 6 (Reuters) - The U.S. Food and Drug Administration said on Wednesday that it has approved Jazz Pharmaceuticals' (JAZZ.O), opens new tab drug to treat diffuse midline glioma, a rare and aggressive tumor, in adults and children aged one year and older. This marks the first FDA approval of a systemic therapy for diffuse midline glioma with a specific mutation that has progressed after previous treatments, the agency said. Diffuse midline glioma (DMG) is a rare and aggressive brain tumor that primarily affects children and young adults. It develops in the brain's and spinal cord's midline structures, such as the brainstem, thalamus, and spinal cord. Jazz Pharmaceuticals acquired the drug in March through its $935 million purchase of Chimerix.
Daily Record
3 hours ago
- Daily Record
Snoring Scots and their sleep-deprived partners offered new treatment from dentists
A new scheme launched this month is allowing selected dental practices to treat noisy sleepers. Scotland's chronic snorers could soon get respite from an unlikely source - a trip to the dentist's. A new scheme launched this month is allowing selected dental practices to treat noisy sleepers. They will be able to prescribe special retainers for chronic snorers who are currently having to wait up to 18 months for hospital treatment on the NHS. Edinburgh dentist Odhran McNichol, of Craigentinny Dental Care, told how his practice is using 3D printing to mould the retainers - called Mandibular Advancement Devices (MADs). He said: "We've seen a steady stream of interest. More often than not, it's the sufferer's partner who brings it up, as they're the ones losing sleep and pushing for a solution. 'Generally people are unaware their dentist can help so most don't think to ask their dentist about sleep problems, it's just not something that crosses their mind. 'There is a lot of information on the internet about treatments for snoring and sleep apnoea, but not all of it is accurate.' More than quarter of Scottish adults are snorers. And around two in three snore so loudly their partner moves to a different bed - known as a "sleep divorce." Participating dentists will be able to prescribe NHS-approved MADs thanks to a training programme run by 32Co. MADs are like a retainer which can be fitted over two sessions, with the user then able to adjust their device manually to suit their mouth. They improve night-time breathing by making your lower jaw move forward slightly, opening your airway while you sleep and reducing noisy snoring. MADs are less bulky and cumbersome than the traditional CPAP breathing masks often prescribed for chronic snorers. McNichol added: 'Of course CPAP devices are gold standard for sleep apnoea, and we would not encourage patients to stop using these. 'But MADs can have a place for heavy snorers who don't necessarily have sleep apnoea as well as patients that struggle with wearing a CPAP or are travelling.' Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you're curious, you can read our Privacy Notice. Outside of the new dentistry scheme, there are only ten 'sleep clinics' in Scotland - three of them in Glasgow - which can treat snoring and sleep-related conditions. Sleep apnoea can lead to other health problems like high blood pressure, heart disease and diabetes. Professor Ama Johal, 32Co Clinical Lead and former Vice-President of the British Society of Dental Sleep Medicine, said: 'Problematic snoring continues to plague millions of people across the UK. '32Co's Aerox Sleep Centres will deliver industry-backed treatment at the convenience of local practices, marking a significant change in the way millions of patients can receive treatment.'
Telegraph
8 hours ago
- Telegraph
Ozempic maker goes to war with ‘fake' copycat jabs as sales slow
The maker of Ozempic and Wegovy has declared war on 'fake' copycat weight-loss jabs as it battles a sales slowdown. Novo Nordisk has filed 14 lawsuits in the United States against companies selling duplicates of its obesity drugs, in an effort to 'safeguard patients from unsafe and unapproved compounded drugs'. The US Food and Drug Administration (FDA) previously allowed copycat drugs to be sold while Novo Nordisk was struggling with shortages of Wegovy, a weight-loss jab, and Ozempic, a diabetes drug that is used off-label for weight loss. The FDA ended that permission in April after production problems eased. However, Novo Nordisk claimed in its lawsuits that companies were continuing to sell the drugs, 'employing tactics that deceive patients into believing compounded products have been reviewed and approved by FDA'. It said companies were doing this 'under the false guise' that the drugs were more personalised versions of its weight-loss drugs. Copycat medicines are often significantly cheaper than Novo Nordisk's branded drugs. While this may welcomed by patients, it means Novo Nordisk is not rewarded for the time and effort it spent developing the treatments. The new legal action comes as Novo Nordisk struggles with a slowdown in sales, which it has blamed on increased competition. As well as copycat versions of its own drugs, the Danish company must compete with rival obesity medicines such as Mounjaro, developed by Eli Lilly. Novo Nordisk reported this week that sales growth had slowed to 16pc in the first half of the year, compared to growth of 25pc last year. Sales of its diabetes and obesity drugs were up 16pc in the first half, versus growth of 26pc in 2024. Shares in the Danish company last week suffered the biggest one-day fall on record after Novo Nordisk slashed its full year sales and profit forecasts. More than €60bn (£52bn) was wiped off the company's value. The board has ousted Lars Fruergaard Jørgensen as chief executive in response to the slowdown. Mr Fruergaard Jørgensen, who is stepping down this week, said he was hopeful that his replacement, Maziar Mike Doustdar, could revive sales. He said: 'With more than one billion people living with obesity globally, including more than 100 million living in the US, and only a few million on treatment, I am confident that under Mike Doustdar's leadership, Novo Nordisk will maximise the significant growth opportunities, supported by a strong product portfolio and future pipeline.' Novo Nordisk is among a group of drug giants that are under pressure to lower prices in the US. Donald Trump wrote to companies last week demanding cheaper medicines. He has claimed pricing in the US needs to be more in line with other countries. On Tuesday, Novo Nordisk said prices for Ozempic on Medicaid were already lower than in some countries in Europe, adding that it was negotiating with the US administration on future prices.
